



Precision oncology, powered by AI

ArteraAI Prostate Test



ArteraAI Prostate Test



Patients diagnosed with localized prostate cancer are faced with many treatment options and uncertainty about what is right for them.

Diagnosis



Treatment

Based on individual patient characteristics, the ArteraAI Prostate Test can provide insight into the following:

- Risk of developing distant metastasis
- Risk of prostate cancer-specific mortality
- Active surveillance as a suitable option^a
- Reduction in risk of distant metastasis by adding short-term androgen deprivation therapy to radiation therapy^b

The ArteraAI Prostate Test can help determine the best cancer treatment plan.

^aFor patients with NCCN very low-, low-, or favorable-intermediate risk.

^bFor patients with NCCN intermediate-risk.

Cost of Test

Artera will work with your insurance company to seek reimbursement for this test. If you have Medicare Fee For Service, there is an established payment rate and you should have no out-of-pocket costs.

If your out-of-pocket costs are greater than \$285, please contact Artera to learn more about available financial assistance programs.

Patients who have questions or wish not to have the test performed should contact Artera and a team member will respond to your inquiry.

How to Order

1.



Physician orders the test.

2.



Existing biopsy sample sent to our lab.

3.




Test results sent to ordering physician.

4.



Patient and physician review results together.

How it Works



Sample Test Results

ARTERA Name: John Doe
Date of Birth: 08/08/1952

ArteraAI Prostate Test Report

PATIENT DETAILS

PATIENT Name: John Doe Date of Birth: 08/08/1952 Condition: Prostate Cancer	PHYSICIAN Name: Adam Smith, MD Clinic Name: Artera Hospital	CLINICAL AND PATHOLOGY Clinical Tumor Stage: T1c Pre-biopsy PSA: 1.8 ng/mL Gleason Score: 7 (3+4) Patient Age at Order Date: 71 NCCN Risk: Favorable Intermediate
ORDER Order Date: 07/01/2023 Artera ID: AM-4V-WBD-005K		

PROGNOSTIC RISK

LOW ArteraAI Prognostic Raw Score=0.33

10-YEAR RISK OF DISTANT METASTASIS

10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY

1.1% 95% CI: 0.7%-1.6%

ACTIVE SURVEILLANCE INSIGHTS (AS) at RP

This patient has a risk of **adverse pathology (AP) at radical prostatectomy (RP)** that is **lower than 63%** of patients who underwent RP in an active surveillance (AS)-managed cohort (N=292).

35th percentile

In this AS-managed cohort, 79% of patients were in the lowest low risk group (10-year risk of distant metastasis <1%).

ST-ADT BIOMARKER

Negative

On average patients with this result had **no clear risk reduction** in distant metastasis with the addition of short-term androgen deprivation therapy.¹

07/07/2023 12:00PM
Review Date and Time (EST)
 Joshua B. Risk, MD
By signing this I am certifying adequate quality of the material received.
(In signing this I am certifying presence of cancer, unless otherwise noted in this report.)

Testing Laboratory: 6800 Southpoint Pkwy, Suite 150, Jacksonville, FL 32216 | CLIA ID: 10D2358449 | Laboratory Director: Joshua B. Risk, MD
© 2024, ARTERA Inc. | TEL: +1 650 385 7940 | FAX: 650 231 6899 | EMAIL: support@artera.ai 1 of 5

1 Prognostic Risk

This biomarker explains the cancer's aggressiveness, presented as the risk of distant metastasis at 10 years.

2 Active Surveillance Insights

For men with lower risk^a prostate cancer, the likelihood of the patient's cancer showing more aggressive features in the future is compared to other patients managed with active surveillance.

3 Predictive Biomarker

For men with NCCN intermediate-risk cancer, this result can help determine if adding ST-ADT will be beneficial.

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Please consult with your health care provider for personalized medical advice and determine if the ArteraAI Prostate Test is appropriate for you.

To learn more:

Visit artera.ai or scan the QR code



For general questions,
please contact:
info@artera.ai

For billing questions,
please contact:
billing@artera.ai
1-650-383-7940

